TY - JOUR T1 - Targeted sequencing of Parkinson’s disease loci genes highlights <em>SYT11, FGF20</em> and other associations JF - medRxiv DO - 10.1101/2020.05.29.20116111 SP - 2020.05.29.20116111 AU - Uladzislau Rudakou AU - Eric Yu AU - Lynne Krohn AU - Jennifer A. Ruskey AU - Farnaz Asayesh AU - Yves Dauvilliers AU - Dan Spiegelman AU - Lior Greenbaum AU - Stanley Fahn AU - Cheryl H. Waters AU - Nicolas Dupré AU - Guy A. Rouleau AU - Sharon Hassin-Baer AU - Edward A. Fon AU - Roy N. Alcalay AU - Ziv Gan-Or Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/25/2020.05.29.20116111.abstract N2 - Genome-wide association studies (GWAS) have identified numerous loci associated with Parkinson’s disease. The specific genes and variants that drive the associations within the vast majority of these loci are unknown. We aimed to perform a comprehensive analysis of selected genes to determine the potential role of rare and common genetic variants within these loci. We fully sequenced 32 genes from 25 loci previously associated with Parkinson’s disease in 2,657 patients and 3,647 controls from three cohorts. Capture was done using molecular inversion probes targeting the exons, exon-intron boundaries and untranslated regions (UTRs) of the genes of interest, followed by sequencing. Quality control was performed to include only high-quality variants. We examined the role of rare variants (minor allele frequency &lt; 0.01) using optimized sequence Kernel association tests (SKAT-O). The association of common variants was estimated using regression models adjusted for age, sex and ethnicity as required in each cohort, followed by a meta-analysis. After Bonferroni correction, we identified a burden of rare variants in SYT11, FGF20 and GCH1 associated with Parkinson’s disease. Nominal associations were identified in 21 additional genes. Previous reports suggested that the SYT11 GWAS association is driven by variants in the nearby GBA gene. However, the association of SYT11 was mainly driven by a rare 3’ UTR variant (rs945006601) and was independent of GBA variants (p=5.23E-05 after exclusion of all GBA variant carriers). The association of FGF20 was driven by a rare 5’ UTR variant (rs1034608171) located in the promoter region. The previously reported association of GCH1 with Parkinson’s Disease is driven by rare nonsynonymous variants, some of which are known to cause dopamine-responsive dystonia. We also identified two LRRK2 variants, p.Arg793Met and p.Gln1353Lys, in ten and eight controls, respectively, but not in patients. We identified common variants associated with Parkinson’s disease in MAPT, TMEM175, BST1, SNCA and GPNMB which are all in strong linkage disequilibrium (LD) with known GWAS hits in their respective loci. A common coding PM20D1 variant, p.Ile149Val, was nominally associated with reduced risk of Parkinson’s disease (OR 0.73, 95% CI 0.60-0.89, p=1.161E-03). This variant is not in LD with the top GWAS hits within this locus and may represent a novel association. These results further demonstrate the importance of fine mapping of GWAS loci, and suggest that SYT11, FGF20, and potentially PM20D1, BST1 and GPNMB should be considered for future studies as possible Parkinson’s disease-related genes.Competing Interest StatementZiv Gan-Or has received consulting fees from Lysosomal Therapeutics Inc., Idorsia, Prevail Therapeutics, Denali, Ono Therapeutics, Deerfield and Inception Sciences (now Ventus). None of these companies were involved in any parts of preparing, drafting and publishing this review. Cheryl H. Waters disclosed the following: Research support (Biogen, Roche, Sanofi); consulting fees (Acorda, Amneal, Impel, Kyowa, Mitsubishi, and Neurocrine); speaker honoraria (Acadia, Acorda, Adamas, Amneal, and US WorldMeds) Funding StatementThis work was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada. The Columbia University cohort is supported by the Parkinson s Foundation, the National Institutes of Health (K02NS080915, and UL1 TR000040) and the Brookdale Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:McGill University Health Center Research Ethics Board - MUHC REB Columbia University Sheba Medical CenterAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data is available upon request by any qualified investigator.AJAshkenazi JewishCADDCombined Annotation Dependent DepletionCIconfidence intervalCNScentral nervous systemDOPAdihydroxyphenylalanineDPdepth of coverageeQTLexpression quantitative trait lociGATKGenome Analysis ToolkitGnomADGenome Aggregation DatabaseGTExGenotype-tissue expressionGWASGenome-wide association studyhg19human genome version 19LDlinkage disequilibriumLOFloss-of-functionMAFminor allele frequencyMIPsmolecular inversion probesNS, Nonsynnon-synonymousORodds ratioQCquality controlREMRapid Eye MovementSKAT-Ooptimized sequence kernel association testsQTLsplicing quantitative trait lociUTRuntranslated regionyoyears of age ER -